Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.48M Buy
52,829
+1,097
+2% +$29.2K 0.54% 41
2025
Q4
$1.29M Buy
51,732
+210
+0.4% +$5.3K 0.47% 46
2025
Q3
$1.31M Buy
51,522
+4,317
+9% +$107K 0.51% 45
2025
Q2
$1.14M Buy
47,205
+14,235
+43% +$332K 0.45% 51
2025
Q1
$835K Buy
32,970
+6,575
+25% +$172K 0.4% 51
2024
Q4
$700K Buy
+26,395
New +$716K 0.33% 52
2023
Q4
Sell
-8,868
Closed -$294K 83
2023
Q3
$294K Sell
8,868
-2,270
-20% -$80.3K 0.24% 60
2023
Q2
$409K Sell
11,138
-5,509
-33% -$214K 0.31% 53
2023
Q1
$679K Buy
16,647
+2,049
+14% +$88.5K 0.57% 39
2022
Q4
$748K Buy
+14,598
New +$700K 0.69% 34

Other funds holding PFE

Ted Buchan & Co's PFE Position: Q1 2026 in Review

Ted Buchan & Co increased its Pfizer (PFE) stake by 2.1% in Q1 2026, buying an estimated $29.2K and bringing the position to 52,829 shares worth $1.48M. The position accounts for 0.54% of the portfolio, ranked #41.

Ted Buchan & Co first reported a position in PFE in Q4 2022 and has held it in 10 quarters since. 2,935 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Ted Buchan & Co held 52,829 shares of Pfizer worth $1.48M as of Q1 2026.
  • Ted Buchan & Co bought 1,097 Pfizer shares in Q1 2026, an estimated $29.2K.
  • Pfizer made up 0.54% of Ted Buchan & Co's portfolio in Q1 2026, its #41 holding.
  • Ted Buchan & Co first reported a position in Pfizer in Q4 2022 and has held it in 10 quarters since.
  • 2,935 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Ted Buchan & Co's 13F filing for Q1 2026, filed 14 May 2026.